Novartis has won approval for its MS drug Gilenya in Russia but still awaits the FDA’s decision on its fate …

Abbott has started enrolment for a phase III trial of daclizumab, a once-monthly injection for relapsing-remitting multiple sclerosis that it …
Novartis’ new oral multiple sclerosis treatment Gilenia has been shown to reduce relapse rates significantly in new trial data.Data presented …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

